VY1706 for Early Alzheimer's Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study
Are You a Good Fit for This Trial?
This trial is for adults aged 55–80 with early Alzheimer's disease or mild cognitive impairment, who are otherwise in good health. People with a family history of inherited Alzheimer's can join from age 30. Participants must have stable medications and a reliable study partner.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- VY1706 High Dose
- VY1706 Low Dose
- VY1706 Mid Dose
Trial Overview
The study tests different doses (low, mid, high) of a new drug called VY1706 to find the safest dose for people with early Alzheimer's disease. It also includes blood tests to monitor immune response.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Voyager Therapeutics
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.